BioAtla Investor Presentation Deck

Focused pipeline with broad applicability of differentiated CAB assets designed to deliver near-term value CAB-ADCS CAB-1/0 CAB- Bispecific TCE CAB Program BA3011 Mecbotamab Vedotin BA3021 Ozuriftamab Vedotin BA3071 BA3182 Additional programs bicatla Target AXL ROR2 CTLA-4 EpCAM x CD3 Various Indications STS & Bone Sarcoma NSCLC Ovarian Cancer* NSCLC Melanoma SCCHN Ovarian Cancer* Multiple tumor types** Adenocarcinoma** Multiple tumor types** Multiple tumor types** IND Enabling Pre-Clinical IIT, investigator-initiated trial; IND, investigational new drug; NSCLC, Non-small Cell Lung Cancer; RCC, Renal Cell Carcinoma; SCCHN, Squamous Cell Carcinoma of the Head and Neck; STS, Soft Tissue Sarcoma. Phase 1 Clinical Phase 2 Clinical Anticipated Milestones ✓ Interim sarcoma results - achieved go criteria to advance multiple subtypes into Phase 2 part 2 Initial interim NSCLC results - achieved go criteria to advance to Phase 2 part 2 ✓ Ovarian IIT dosing Phase 2 interim NSCLC data and melanoma update 2H22 SCCHN trial dosing 4Q ✓ Ovarian IIT dosing ✓ Phase 1 / 2 dosing IND submission and Phase 1 initiation 2H2022 2023 and beyond * Phase 2 investigator-initiated trial for Ovarian Cancer ** Indications based upon tumor target expression BioAtla| Overview 7

View entire presentation